Dengue Vaccines and Antivirals Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
See the next evidence inflection points before they arrive. This readout-outlook report connects Clinical Trials, Drug & Asset, and Company & Deal Intelligence data through PatSnap MCP Servers. Explore the PatSnap MCP Marketplace to monitor the same endpoint, sponsor and timing signals inside your own AI workflow.
MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. This is strategic research, not medical advice. Trial status, endpoints and timing can change; confirm the underlying records before making decisions.
Readout outlook: why this landscape matters now
Dengue Vaccines and Antivirals remains an active clinical development field. The landscape is diversifying across prevention, early treatment and high-risk populations, making variant coverage, resistance, seasonality and practical delivery central to differentiation. The PatSnap evidence set used here contains 158 matched trial records and 74 indexed result records before the decision-focused sample below was selected. This companion outlook shifts the decision lens from market breadth to evidence timing: which endpoints can change practice, which sponsors can execute across geographies, and where the next readout may still leave uncertainty.
MCP workflow for a readout-focused landscape
The analysis starts with Clinical Trials MCP and clinical_trial_fetch to align phase, recruitment status, sponsor, countries, primary endpoints and completion dates. clinical_trial_result_fetch then separates already indexed evidence from future catalysts. Drug & Asset drug_fetch adds mechanism and global development status; Company & Deal Intelligence organization_fetch adds sponsor context. Use PatSnap MCP Servers to keep each layer traceable instead of inferring asset or company facts from trial titles.
Trial, endpoint and expected-readout map
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07600879 | Intervention not normalized | Not Applicable; Not yet recruiting | Sponsor not listed | Brazil | Muscle fatigue assessed by surface electromyography (Baseline and immediately after completion of the intervention protocol) | 2027-07-01 |
| NCT07602920 | Intervention not normalized | Not Applicable; Not yet recruiting | University of Oxford | Bangladesh | Level of gut leakage marker in blood and gastrointestinal findings in POCUS (On enrollment, day of development of severity if non severe at enrolment, up…) | 2027-01-31 |
| NCT07576868 | Niclosamide | Phase 2/3; Recruiting | HYUNDAI BIOSCIENCE Co., Ltd. | Vietnam | [Part 1] Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) (From start of study intervention (Day 1) up to end of safety follow-up (Day 29)); [Part 1] Average of dengue viral load on Day 3 (Baseline, Day 1, 2, 3) | 2027-01-01 |
| NCT07543458 | Baricitinib + Dexamethasone Sodium Phosphate + Acetylcysteine | Phase 3; Not yet recruiting | Oxford University Clinical Research Unit, Vietnam | Colombia, Vietnam, Bangladesh, Philippines, Brazil +5 more | Progression to severe dengue/critical dengue (between randomization to hospital discharge (average of 5 days)); All-cause mortality within 30 days (Day 30) | 2030-07-31 |
Read the table horizontally. Phase shows nominal maturity, but endpoint choice shows what the study can actually prove; geography signals operational breadth; and expected timing reveals whether a program is a near-term catalyst or a long-duration strategic bet.
Readout signals already on record
- Phase 1 Trial to Model Primary, Secondary, and Tertiary Dengue Using a Monovalent Vaccine (Phase 1): the indexed record reports Injection site pain = 4 Participants; Injection site pain = 0 Participants; Injection site pain = 0 Participants.
- Humoral and cellular responses to a tetravalent dengue vaccine (TAK-003) in adults from a dengue non-endemic region: An open-label phase 2 trial (Phase 2): the indexed record reports AE = Vaccine RNAemia and safety findings were consistent with the known TAK-003 safety profile.
- Long-term efficacy and safety of the single-dose tetravalent Butantan dengue vaccine (Phase 3): the indexed record reports VE(against DENV-1 (95% CI)) = 73.0 %.
These signals are anchors, not league tables. Differences in population, prior treatment, baseline risk, estimand, endpoint definition and follow-up can overwhelm apparent numerical comparisons. The useful question is which uncertainty each result resolves before the next catalyst.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
How assets and sponsors shape readout probability
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Niclosamide (Phase 2/3), Baricitinib (Approved; JAK1 x JAK2), Dexamethasone Sodium Phosphate (Approved; GR), Acetylcysteine (Approved; Free radicals). Company & Deal Intelligence records identify sponsor context for University of Oxford, HYUNDAI BIOSCIENCE Co., Ltd. (048410), Oxford University Clinical Research Unit, Vietnam. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Evidence white space before the next readout cycle
- Clinically meaningful endpoints paired with virologic or microbiologic measures.
- Evidence in immunocompromised, pediatric, pregnant and older populations.
- Resistance surveillance and combination strategies for prolonged infection.
- Coadministration, real-world effectiveness and implementation studies.
Readout-risk implications
A crowded field does not guarantee a crowded evidence set. Programs can still differentiate through an active comparator, a clinically meaningful endpoint, a biomarker-defined responder group, broader geography, or a credible sequencing plan. Sponsors should pressure-test whether the planned readout will close a decision gap; BD teams should distinguish mechanism novelty from evidence novelty; investors should track endpoint maturity and execution risk alongside phase.
Readout watchlist
Monitor recruitment changes, protocol amendments, primary-completion dates, new result indexing, sponsor ownership and multinational expansion. Re-run the MCP workflow as a delta analysis. A change from surrogate to clinical outcome, a delayed completion date, a new active comparator or a scaled partner can materially alter the probability and strategic meaning of the next readout.
Bottom line
Dengue Vaccines and Antivirals has multiple clinical catalysts, but their value depends on endpoint quality, execution and context. A readout outlook is most useful when it joins trial design, indexed results, asset mechanism and sponsor capacity in one traceable view.
Build your own readout monitor: Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable components for catalyst tracking and SEO-ready reports.
